Product Pathways - Growth Factors/Cytokines
Mouse His6Interleukin-33 (mHis6IL-33) #6983
|6983LF||50 µg (Carrier Free)||---||In Stock||---|
|6983LC||50 µg (With Carrier)||---||In Stock||---|
|6983SC||10 µg (With Carrier)||---||In Stock||---|
|6983SF||10 µg (Carrier Free)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant mouse His6IL-33 (mHis6IL-33) Ser109-Ile266 (Accession #NP_598536) was produced in E.coli at Cell Signaling Technology.
Recombinant N-terminally His6-tagged mIL-33 has a calculated MW of 19,439. DTT-reduced and non-reduced protein migrate as 22 kDa polypeptides.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mHis6IL-33. All lots are greater than 98% pure.
The bioactivity of recombinant mHis6IL-33 was determined by its ability to induce IL-13 production by MC/9 cells. The ED50 of each lot is between 1-6 ng/ml.
The purity of recombinant mHis6IL-33 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mHis6IL-33 and staining overnight with Coomassie Blue.
Less than 0.01 ng endotoxin/1 μg mHis6IL-33.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 1 mM EDTA, 3 mM DTT and 20 μg BSA per 1 μg mHis6IL-33. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 1 mM EDTA and 3 mM DTT.
IL-33 is a novel member of the IL-1 family of proteins that was discovered in a computational search to identify unknown family members (1). IL-33 is expressed by fibroblasts and endothelial cells, and is upregulated in response to inflammatory stimuli (1). IL-33 plays a key role in Th2 type inflammatory responses, including atopic allergic responses and asthma (1,2). The IL-33 receptor consists of the ST2 and IL-1 accessory protein (IL-1-Acp) (1,3). ST2 is expressed on mast cells, basophils and Th2 cells (1). In addition to its putative role as a Th2 cytokine, IL-33 also contains a nuclear localization domain and may function as a nuclear factor (4,5). The nuclear function of IL-33 remains unclear. IL-33 is released by cellular necrosis, similar to other “alarmins”, thereby signaling tissue injury (5,6). However, more recent data suggests that IL-33 may also be actively secreted from live cells via a non-classical mechanism (7).
- Liew, F.Y. et al. (2010) Nat Rev Immunol 10, 103-10.
- Chackerian, A.A. et al. (2007) J Immunol 179, 2551-5.
- Borish, L. and Steinke, J.W. (2011) Curr Allergy Asthma Rep 11, 7-11.
- Moussion, C. et al. (2008) PLoS One 3, e3331.
- Cayrol, C. and Girard, J.P. (2009) Proc Natl Acad Sci U S A 106, 9021-6.
- Lüthi, A.U. et al. (2009) Immunity 31, 84-98.
- Kakkar, R. et al. (2012) J Biol Chem 287, 6941-8.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.